Boulder’s Edgewise Therapeutics reveals $176M IPO plan after confidential filing
This story was updated at 2 p.m. Mountain Time with Edgewise’s closing stock price.
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) kicked off its initial public offering Friday morning, marking the latest biotechnology company in the Boulder area to go public in recent months.
In a statement, the company said it will offer 11 million shares at $16 per share, with the goal to pull in $176 million in funding before deducting underwriting fees and other charges. Its underwriters have an option to buy $26.4 million in additional stock at their discretion.
The stock closed at $30 per share on Friday, marking an…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Tilled Inc., a Boulder payment-facilitation technology company, recently completed a $12.5 million investment round, bringing…
-
A trio of Boulder startup scene veterans is reviving the local Techstars accelerator program, which…
-
Brightwave, Boulder-based AI technology company is “swinging for the fences,” after raising $21 million to…
-
Playa Bowls, a national restaurant chain specializing in fruit bowls and smoothies, will soon open…
